Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Real-world insights into chronic inflammatory demyelinating polyneuropathy management

Franz Felix Konen • 28 Jun 2026
EAN 2026
Neuromuscular Disorders Antibodies Azathioprine Bortezomib Ciclosporin Dexamethasone Methotrexate Methylprednisolone Mycophenolate Rituximab

Franz Felix Konen, MD, PhD, Hannover Medical School, Hannover, Germany, discusses findings from a multicenter analysis of chronic inflammatory demyelinating polyneuropathy (CIDP) management across specialized German centers. He highlights considerable variation in treatment strategies compared with guideline recommendations, with IVIg and glucocorticoids remaining the most common first-line therapies. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Franz Felix Konen

Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026
Preliminary results of PRO-KFLC: kappa-free light chains and oligoclonal bands in MS diagnosis
3:00
Preliminary results of PRO-KFLC: kappa-free light chains and oligoclonal bands in MS diagnosis
Franz Felix Konen • 28 Jun 2026

Related Videos

The mechanisms underlying multifocal motor neuropathy
1:21
The mechanisms underlying multifocal motor neuropathy
Nicolas Dubuisson • 27 Jun 2026
Improving the transition to adult sleep care for young people with neuromuscular disorders
2:03
Improving the transition to adult sleep care for young people with neuromuscular disorders
Umakanth Katwa • 17 Jun 2026
Sustained disease control with nipocalimab in gMG: post-hoc analysis of Vivacity-MG3
4:33
Sustained disease control with nipocalimab in gMG: post-hoc analysis of Vivacity-MG3
Richard Nowak • 28 Jun 2026
Findings from a Phase I trial of autologous SVF therapy in ALS
2:16
Findings from a Phase I trial of autologous SVF therapy in ALS
Zenglin Cai • 27 Jun 2026
The content of VJNeurology is intended for healthcare professionals